Subhadra Jayaraman
About Subhadra Jayaraman
Subhadra Jayaraman is a Senior Scientist I at Mammoth Biosciences, specializing in immunology and oncology. With a PhD in Bioengineering from Binghamton University, she has extensive experience in cancer research and genome engineering.
Work at Mammoth Biosciences
Subhadra Jayaraman has been employed at Mammoth Biosciences since 2022 as a Senior Scientist I. In this role, she focuses on immunology and oncology targets as part of the genome engineering and protein discovery team. Prior to this position, she worked as a Scientist in Genome Editing Immunology at the same company from 2021 to 2022. Her work contributes to advancements in the field of genome engineering and the development of innovative therapeutic solutions.
Education and Expertise
Subhadra Jayaraman earned her Doctor of Philosophy (PhD) in Bioengineering and Biomedical Engineering from Binghamton University, where she studied from 2014 to 2019. She also holds a Bachelor of Technology (B Tech) in Biotechnology from Anna University, completed from 2006 to 2010. Her academic background provides her with a solid foundation in biomedical research, particularly in immunology and cancer therapy.
Background
Subhadra Jayaraman has a diverse professional background in biomedical research. She began her career as a Trainee at Advinus Therapeutics in 2010, followed by roles as a Research Associate at bigtec Labs and a Research Engineer at Siemens Technology and Services India. She later served as a Summer Research Intern at Novartis Institutes for BioMedical Research in 2017. After completing her PhD, she worked as a Postdoctoral Fellow at Merck from 2019 to 2021, where she developed 3D tumor models for studying T cell biology.
Research Interests
Subhadra Jayaraman's research interests encompass personalized cancer therapy, cancer-immune system interactions, point-of-care diagnostics, and genome engineering. She has a comprehensive understanding of nucleic acid-based assay development, particularly for diagnosing infectious diseases in low-resource settings. Her expertise in these areas supports her contributions to innovative research and development in the field of immunology and oncology.